• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

动脉高血压患者血清中分子量为15kD的蛋白质成分的存在与血清对钠钾ATP酶的抑制作用之间是否存在关联?

[Is there a relation between the presence in the serum of patients with arterial hypertension of a protein component with molecular weight of 15 kD and the inhibitory effect of the serum on Na,K-ATPase?].

作者信息

Rogaeva E A, Perova N V, Aleksandrov A A, Oganov R G, Lopina O D

出版信息

Vopr Med Khim. 1987 Jul-Aug;33(4):34-9.

PMID:2821695
Abstract

Blood sera from patients with arterial hypertension exhibited more distinct inhibitory effect on purified Na+,K+-ATPase as compared with blood sera of healthy persons. Moreover, the fraction of 12-15 kDa protein components was usually increased in blood sera of the patients. At the same time, strong inhibition of the enzyme occurred after addition of blood sera which did not contain the protein fraction. The data obtained suggest that both these patterns--the degree of blood sera inhibitory effect on Na+,K+-ATPase activity and content of 12-15 kDa protein components in blood serum--should be considered as diagnostically valuable at early steps of development of hypertension.

摘要

与健康人的血清相比,动脉高血压患者的血清对纯化的钠钾ATP酶表现出更明显的抑制作用。此外,患者血清中12 - 15 kDa蛋白质成分的比例通常会增加。同时,添加不含该蛋白质成分的血清后,该酶也会受到强烈抑制。所获得的数据表明,这两种模式——血清对钠钾ATP酶活性的抑制程度以及血清中12 - 15 kDa蛋白质成分的含量——在高血压发展的早期阶段都应被视为具有诊断价值。

相似文献

1
[Is there a relation between the presence in the serum of patients with arterial hypertension of a protein component with molecular weight of 15 kD and the inhibitory effect of the serum on Na,K-ATPase?].动脉高血压患者血清中分子量为15kD的蛋白质成分的存在与血清对钠钾ATP酶的抑制作用之间是否存在关联?
Vopr Med Khim. 1987 Jul-Aug;33(4):34-9.
2
Reduction of erythrocyte (Na(+)-K+)ATPase activity in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria.2型(非胰岛素依赖型)微量白蛋白尿糖尿病患者红细胞(钠 - 钾)ATP酶活性降低。
Horm Metab Res. 1994 Jan;26(1):33-8. doi: 10.1055/s-2007-1000768.
3
Increased concentrations of a circulating sodium pump inhibitor in essential hypertension and uraemia and its partial purification from haemofiltrate.原发性高血压和尿毒症患者循环中钠泵抑制剂浓度升高及其从血液滤过液中的部分纯化。
Physiol Bohemoslov. 1990;39(1):79-85.
4
Endogenous inhibitors of the Na+, K(+)-pump and platelet Ca2+ handling in hypertension.
Physiol Bohemoslov. 1990;39(1):71-8.
5
Endogenous Na+ transport inhibitor in human hypertension: further biochemical and chemical studies.人类高血压中的内源性钠离子转运抑制剂:进一步的生化与化学研究
Klin Wochenschr. 1987;65 Suppl 8:146-53.
6
Recent progress on an endogenous digitalislike factor in hypertension.
J Clin Hypertens. 1986 Jun;2(2):93-100.
7
[The role of an endogenous digoxin-like factor in regulating blood circulation and in the origin of arrhythmia in myocardial ischemia].[内源性洋地黄样因子在调节血液循环及心肌缺血性心律失常发生机制中的作用]
Ter Arkh. 1989;61(7):84-9.
8
The role of endogenous Na+, K(+)-adenosine triphosphatase inhibitory factor in the regulation of membrane fluidity of erythrocytes in essential hypertension.内源性钠钾-三磷酸腺苷酶抑制因子在原发性高血压患者红细胞膜流动性调节中的作用
J Hypertens. 1992 Jul;10(7):657-61.
9
Volume expansion in renal failure patients: a paradigm for a clinically relevant [Na,K]ATPase inhibitor.肾衰竭患者的容量扩张:一种具有临床相关性的[钠,钾]ATP酶抑制剂的范例。
J Cardiovasc Pharmacol. 1993;22 Suppl 2:S54-7.
10
[Changes in the activity of Na+ K+ ATPase in erythrocytes and immunoreactive plasma digoxin-like substances in chronic renal insufficiency: their relation to blood pressure levels].
Vnitr Lek. 1988 Sep;34(9):843-50.

引用本文的文献

1
Identification, purification and partial characterization of low molecular weight protein inhibitor of Na⁺/K⁺-ATPase from pulmonary artery smooth muscle cells.肺动脉平滑肌细胞中Na⁺/K⁺-ATP酶低分子量蛋白抑制剂的鉴定、纯化及部分特性分析
Mol Cell Biochem. 2014 Aug;393(1-2):309-17. doi: 10.1007/s11010-014-2075-6. Epub 2014 May 22.